Journal of Asia Pacific Aesthetic Sciences

Hafsah Sazali

Abstract: Hyperpigmentation disorders, including melasma, post-inflammatory hyperpigmentation (PIH), and other forms of dyschromia, are common dermatological concerns. Topical product formulated with cysteamine, a naturally occurring antioxidant has shown efficacy in treating hyperpigmentation in previous studies. This case series evaluates the efficacy and safety of a topical cysteamine-based product in treating hyperpigmentation disorders in eight patients. Eight patients (7 female, 1 male) with varying forms of hyperpigmentation were treated with a topical cysteamine-based cream. Retrospective clinical evaluations including visual assessment and patient-reported outcomes were conducted pre & post treatment. By week 12, all patients demonstrated a reduction in hyperpigmentation. The most significant changes were observed in melasma and PIH patients. Patient-reported outcomes reflected satisfaction with the product’s efficacy and tolerability. Mild irritation was reported as a side effect and no severe adverse effects were noted. Topical cysteamine product demonstrated efficacy in reducing hyperpigmentation in this case series, with a favourable safety profile. Further studies with larger cohorts and long-term follow-up are warranted to validate these findings.